EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status

Ziheng Xu, Jacqueline V Aredo, Chloe C Su, Nathaniel J Myall, Mohana Roy, Kavitha J Ramchandran, Heather A Wakelee, Joel W Neal

Cancer Treatment and Research Communications · 2026 · 47 · 101227

DOI: 10.1016/j.ctarc.2026.101227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Ziheng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Kelch-Like ECH-Associated Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Kelch-Like ECH-Associated Protein 1SmokingHumansFemaleMaleMutationMiddle AgedAgedRetrospective StudiesAged, 80 and overProgression-Free SurvivalPiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

ECOG performance statusKEAP1 mutationKRAS inhibitorNSCLCSmoking history

Substanzen

Proto-Oncogene Proteins p21(ras)Kelch-Like ECH-Associated Protein 1KEAP1 protein, humanKRAS protein, humansotorasibPiperazinesPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
  • Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: jwneal@stanford.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Xu, Z., Aredo, J. V., Su, C. C., Myall, N. J., Roy, M., Ramchandran, K. J., Wakelee, H. A., & Neal, J. W. (2026). KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status. Cancer Treatment and Research Communications, 47, 101227. https://doi.org/10.1016/j.ctarc.2026.101227

Vancouver

Xu Z, Aredo JV, Su CC, Myall NJ, Roy M, Ramchandran KJ, et al. KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status. Cancer Treatment and Research Communications. 2026;47:101227. doi:10.1016/j.ctarc.2026.101227

BibTeX
@article{Xu2026,
  author = {Xu, Ziheng and Aredo, Jacqueline V and Su, Chloe C and Myall, Nathaniel J and Roy, Mohana and Ramchandran, Kavitha J and Wakelee, Heather A and Neal, Joel W},
  title = {KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {47},
  pages = {101227},
  doi = {10.1016/j.ctarc.2026.101227}
}
Kostenlos starten →